Highline Capital Management, L.P. Passage Bio, Inc. Transaction History

Highline Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $312,000 - $509,999	50,000 Added 4.22%	1,235,869 $7.85 Million
Q3 2021 Nov 15, 2021	BUY	$9.73 - $15.52 $1.83 Million - $2.92 Million	188,363 Added 18.88%	1,185,869 $11.8 Million
Q2 2021 Aug 16, 2021	BUY	$12.44 - $19.45 $1.57 Million - $2.46 Million	126,558 Added 14.53%	997,506 $13.2 Million
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $4.36 Million - $8.02 Million	268,700 Added 44.62%	870,948 $15.2 Million
Q4 2020 Feb 16, 2021	BUY	$14.28 - $29.73 $30,287 - $63,057	2,121 Added 0.35%	602,248 $15.4 Million
Q3 2020 Nov 16, 2020	SELL	$12.39 - $26.15 $588,301 - $1.24 Million	-47,482 Reduced 7.33%	600,127 $7.87 Million
Q2 2020 Aug 14, 2020	BUY	$14.59 - $36.07 $4.06 Million - $10 Million	278,277 Added 75.35%	647,609 $17.7 Million
Q1 2020 May 15, 2020	BUY	$8.86 - $22.2 $3.27 Million - $8.2 Million	369,332 New	369,332 $5.82 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $31M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.